Talazoparib Tosylate

DRUG6 trials

Sponsors

Melinda Telli, SWOG Cancer Research Network, Roswell Park Cancer Institute, M.D. Anderson Cancer Center, Stanford University

Conditions

Advanced Breast CancerAdvanced Lung Non-Squamous Non-Small Cell CarcinomaAdvanced Malignant Solid NeoplasmBreast CancerClinical Stage III Gastroesophageal Junction AdenocarcinomaClinical Stage IV Gastroesophageal Junction AdenocarcinomaClinical Stage IVA Gastroesophageal Junction AdenocarcinomaClinical Stage IVB Gastroesophageal Junction Adenocarcinoma A

Phase 1

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT04207190

Roswell Park Cancer InstituteRecurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

Start: 2020-10-23End: 2024-06-29Updated: 2024-11-01

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

RecruitingNCT04511039

Roswell Park Cancer InstituteAdvanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma +26

Start: 2021-06-08End: 2027-04-01Target: 45Updated: 2026-03-02

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

RecruitingNCT04693468

M.D. Anderson Cancer CenterAdvanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm

Start: 2020-12-01End: 2027-12-31Target: 111Updated: 2026-03-13

Phase 2

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

CompletedNCT02401347

Melinda TelliAdvanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer

Start: 2015-08-31End: 2022-12-31Updated: 2023-02-21

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

CompletedNCT04173507

SWOG Cancer Research NetworkAdvanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8 +2

Start: 2020-02-14End: 2024-05-01Updated: 2024-09-03

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

WithdrawnNCT04756765

Stanford UniversityAdvanced Breast Cancer, Breast Cancer

Start: 2023-02-23End: 2024-12-18Updated: 2025-08-17

Related Papers

Abstract 6762: A novel therapeutic approach for targeting p53-mutant cancers by leveraging DNA damage response vulnerabilities

Cancer Research2026-04-03

Abstract B001: Effective targeting p53 mutant pancreatic cancer by novel drug-combination strategy leveraging their DNA damage liabilities

Cancer Research2025-09-28

Abstract P3-08-27: Novel Combination Immune Therapy for Metastatic Breast Cancers leveraging weaknesses in DNA damage response in p53 Mutant cancer

Clinical Cancer Research2025-06-13

Abstract 5991: Novel triple-drug combination strategy for p53 mutant cancers leveraging their DNA damage response liabilities

Cancer Research2025-04-21

Abstract 7590: Novel therapeutic approach for targeting p53 mutant colorectal cancers by affecting post-replicative DNA repair

Cancer Research2024-03-22

A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes

Nature Cancer2022-10-17123 citations

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic <i>STK11 </i>genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology2022-06-013 citations

Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+ Relapsed or Refractory Acute Myeloid Leukemia

Blood2021-11-052 citations

A Phase I Trial of Talazoparib in Patients with Advanced Hematologic Malignancies

International Journal of Hematologic Oncology2021-09-017 citations

Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia

Blood2020-11-043 citations

Abstract P6-08-28: Comprehensive germline multigene panel testing changes clinical care for patients with breast cancer

Cancer Research2020-02-15

Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in <i>BRCA1</i> and <i>BRCA2</i> wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.

Journal of Clinical Oncology2019-05-2048 citations

Abstract P5-09-03: Expanded panel testing superior to BRCA1/2 and breast cancer panel in patients with breast cancer

Cancer Research2019-02-15

Beyond BRCA1/2: Clinician-reported utility 3 years post panel testing.

Journal of Clinical Oncology2018-05-20